Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Endeavour Silver resumes Terronera operations after August blockade suspension

Endeavour Silver resumes Terronera operations after August blockade suspension

BitgetBitget2026/10/08 10:52

Endeavour Silver reported a blockade that suspended Terronera mine operations from Aug. 12 to Aug. 24, 2026. The disruption reduced Terronera throughput to 165,171 tonnes in Q3 2026 from 175,729 tonnes in Q2. Guanaceví’s mill was taken offline on Sept. 21 to replace the primary mill head and trunnion. Repairs are expected to finish in the first half of October, with processing continuing at lower throughput. Company flagged a recalculation of full-year production and cost guidance, with output expected at or slightly below the low end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endeavour Silver Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006526), on October 08, 2026, and is solely responsible for the information contained therein.

  • Endeavour Silver reported a blockade that suspended Terronera mine operations from Aug. 12 to Aug. 24, 2026.
  • The disruption reduced Terronera throughput to 165,171 tonnes in Q3 2026 from 175,729 tonnes in Q2.
  • Guanaceví’s mill was taken offline on Sept. 21 to replace the primary mill head and trunnion.
  • Repairs are expected to finish in the first half of October, with processing continuing at lower throughput.
  • Company flagged a recalculation of full-year production and cost guidance, with output expected at or slightly below the low end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endeavour Silver Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006526), on October 08, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11

BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11